Home
Markets
Charts & Ideas
Algo
News
Store
Brokers
Download
Economic Calendar
Trading Signals
WebTerminal
Heatmap
Type
/
to search: @user, $symbol
Search
Log in
Create an account
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
M
MEDI
Harbor Health Care ETF
31.4
8
USD
+0.10%
Sector:
Financial
Base:
USD
Profit Currency:
USD
Daily Range
Year Range
Daily Change
+0.10%
Monthly Change
+7.66%
6 month change
+0.45%
Year Change
+0.45%
Previous Close
31.4
5
Open
31.4
8
Low
31.4
8
High
31.4
8
Volume
1
Markets
US ETFs
MEDI
Open full chart
Full chart
Overview
All holdings
Heatmap
Top holdings
Market Value
Shares
Weight %
MRK
Merck & Co Inc
415.7 K
3 770.0
1.6%
IDXX
IDEXX Laboratories Inc
402.9 K
601.0
1.5%
TECH
Bio-Techne Corp
394.9 K
6 162.0
1.5%
PODD
Insulet Corp
339.5 K
1 327.0
1.3%
DXCM
Dexcom Inc
261.0 K
3 573.0
1.0%
RDNT
RadNet Inc
240.4 K
3 429.0
0.9%
ALNY
Alnylam Pharmaceuticals Inc
215.0 K
636.0
0.8%
HQY
HealthEquity Inc
200.8 K
2 344.0
0.8%
NAMS
Newamsterdam Pharma Co NV
191.5 K
6 153.0
0.7%
BIO
Bio-Rad Laboratories Inc
181.5 K
618.0
0.7%
IONS
Ionis Pharmaceuticals Inc
163.6 K
1 979.0
0.6%
GH
Guardant Health Inc
154.8 K
1 357.0
0.6%
ADPT
Adaptive Biotechnologies Corp
145.1 K
7 841.0
0.5%
IRTC
IRhythm Holdings Inc
134.7 K
872.0
0.5%
IMVT
Immunovant Inc
133.5 K
5 136.0
0.5%
ICLR
ICON PLC
129.2 K
717.0
0.5%
BCYC
Bicycle Therapeutics PLC
96.4 K
15.0 K
0.4%
1
2
News
2 Best ETFs to Buy in April 2026, According to Analysts - TipRanks.com
Harbor Health Care ETF Q4 2025 Portfolio Review
Eight stock picks to play one of the healthiest corners of the market
Eli Lilly Hits $1 Trillion Milestone: ETFs to Invest in
Opinion: Biotech is back. Here’s why these rallying stocks belong in your portfolio now.
Medistim Q3 2025 presentation: Revenue surges 25.7% as EBIT climbs 27.1%
Earnings call transcript: Medistim’s Q3 2025 results show strong growth
Harbor Health Care ETF Q2 2025 Commentary (NYSEARCA:MEDI)
Time to Buy UnitedHealth-Heavy ETFs?
Poland stocks lower at close of trade; WIG30 down 0.35%
Earnings call transcript: Medistim Q2 2025 sees stock surge 14% on strong growth
Medistim Q2 2025 presentation: Revenue up 16.7%, EBIT surges 31.2%
